Zobrazeno 1 - 10
of 940
pro vyhledávání: '"Jesús-F. San Miguel"'
Autor:
María-Victoria Mateos, Albert Oriol, Laura Rosiñol, Felipe de Arriba, Noemí Puig, Jesús Martín, Joaquín Martínez-López, María Asunción Echeveste, Josep Sarrá, Enrique Ocio, Gemma Ramírez, Rafael Martínez, Luis Palomera, Angel Payer, Rebeca Iglesias, Javier de la Rubia, Adrian Alegre, Ana Isabel Chinea, Joan Bladé, Juan José Lahuerta, Jesús-F. San Miguel
Publikováno v:
Haematologica, Vol 100, Iss 8 (2015)
Bendamustine is a bifunctional alkylating agent with proven activity in myeloma. In this study 60 newly diagnosed myeloma patients were given bendamustine plus bortezomib and prednisone in a regimen consisting of one cycle of bortezomib twice weekly
Externí odkaz:
https://doaj.org/article/8f433fa5fdd94af095c27fe5380f3d51
Autor:
Cristina Encinas, José-Ángel Hernandez-Rivas, Albert Oriol, Laura Rosiñol, María-Jesús Blanchard, José-María Bellón, Ramón García-Sanz, Javier de la Rubia, Ana López de la Guía, Ana Jímenez-Ubieto, Isidro Jarque, Belén Iñigo, Victoria Dourdil, Felipe de Arriba, Clara Cuéllar Pérez-Ávila, Yolanda Gonzalez, Miguel-Teodoro Hernández, Joan Bargay, Miguel Granell, Paula Rodríguez-Otero, Maialen Silvent, Carmen Cabrera, Rafael Rios, Adrián Alegre, Mercedes Gironella, Marta-Sonia Gonzalez, Anna Sureda, Antonia Sampol, Enrique M. Ocio, Isabel Krsnik, Antonio García, Aránzazu García-Mateo, Joan-Alfons Soler, Jesús Martín, José-María Arguiñano, María-Victoria Mateos, Joan Bladé, Jesús F. San-Miguel, Juan-José Lahuerta, Joaquín Martínez-López, GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 4, Pp 1-8 (2022)
Abstract Infections remain a common complication in patients with multiple myeloma (MM) and are associated with morbidity and mortality. A risk score to predict the probability of early severe infection could help to identify the patients that would
Externí odkaz:
https://doaj.org/article/fcb4c3d2e7254e4d93afeee7eb8db18a
Autor:
Sara Villar, Beñat Ariceta, Xabier Agirre, Aura Daniela Urribarri, Rosa Ayala, David Martínez-Cuadrón, Juan Miguel Bergua, Susana Vives, Lorenzo Algarra, Mar Tormo, Pilar Martínez, Josefina Serrano, Catia Simoes, Pilar Herrera, Maria José Calasanz, Ana Alfonso-Piérola, Bruno Paiva, Joaquín Martínez-López, Jesús F. San Miguel, Felipe Prósper, Pau Montesinos
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Acute myeloid leukemia (AML) in the elderly remains a clinical challenge, with a five-year overall survival rate below 10%. The current ELN 2017 genetic risk classification considers cytogenetic and mutational characteristics to stratify fit AML pati
Externí odkaz:
https://doaj.org/article/3518c66232c441da81dbca6328896425
Autor:
Noemi Puig, Miguel T. Hernández, Laura Rosiñol, Esther González, Felipe de Arriba, Albert Oriol, Verónica González-Calle, Fernando Escalante, Javier de la Rubia, Mercedes Gironella, Rafael Ríos, Ricarda García-Sánchez, José M. Arguiñano, Adrián Alegre, Jesús Martín, Norma. C. Gutiérrez, María J. Calasanz, María L. Martín, María del Carmen Couto, María Casanova, Mario Arnao, Ernesto Pérez-Persona, Sebastián Garzón, Marta S. González, Guillermo Martín-Sánchez, Enrique M. Ocio, Morton Coleman, Cristina Encinas, Ana M. Vale, Ana I. Teruel, María Cortés-Rodríguez, Bruno Paiva, M. Teresa Cedena, Jesús F. San-Miguel, Juan J. Lahuerta, Joan Bladé, Ruben Niesvizky, María-Victoria Mateos
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 5, Pp 1-11 (2021)
Abstract Although case-control analyses have suggested an additive value with the association of clarithromycin to continuous lenalidomide and dexamethasone (Rd), there are not phase III trials confirming these results. In this phase III trial, 286 p
Externí odkaz:
https://doaj.org/article/fb9a610fa208459ba3fc58d65716e220
Autor:
Leire Burgos, Noemi Puig, Maria-Teresa Cedena, María-Victoria Mateos, Juan José Lahuerta, Bruno Paiva, Jesús F. San-Miguel
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-8 (2020)
Abstract The landscape of multiple myeloma (MM) has changed considerably in the past two decades regarding new treatments, insight into disease biology and innovation in the techniques available to assess measurable residual disease (MRD) as the most
Externí odkaz:
https://doaj.org/article/64ad9cf505d74164ad353558e6739939
Autor:
Ana-Alicia López-Iglesias, Ana B. Herrero, Marta Chesi, Laura San-Segundo, Lorena González-Méndez, Susana Hernández-García, Irena Misiewicz-Krzeminska, Dalia Quwaider, Montserrat Martín-Sánchez, Daniel Primo, Teresa Paíno, P. Leif Bergsagel, Thomas Mehrling, Marcos González-Díaz, Jesús F. San-Miguel, María-Victoria Mateos, Norma C. Gutiérrez, Mercedes Garayoa, Enrique M. Ocio
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-14 (2017)
Abstract Background Despite recent advances in the treatment of multiple myeloma (MM), the prognosis of most patients remains poor, and resistance to traditional and new drugs frequently occurs. EDO-S101 is a novel therapeutic agent conceived as the
Externí odkaz:
https://doaj.org/article/bfebf6dd497c42b797a071d86cc0e1d4
Autor:
María-Victoria Mateos, Heinz Ludwig, Ali Bazarbachi, Meral Beksac, Joan Bladé, Mario Boccadoro, Michele Cavo, Michel Delforge, Meletios A. Dimopoulos, Thierry Facon, Catarina Geraldes, Hartmut Goldschmidt, Roman Hájek, Markus Hansson, Krzysztof Jamroziak, Merav Leiba, Tamás Masszi, Larisa Mendeleeva, Michael O’Dwyer, Torben Plesner, Jesús F. San-Miguel, Christian Straka, Niels W.C.J. van de Donk, Kwee Yong, Samo Zver, Philippe Moreau, Pieter Sonneveld
Publikováno v:
HemaSphere, Vol 3, Iss 1 (2019)
Abstract. The introduction of new agents and management strategies over the past decade has resulted in a major step change in treatment outcomes with deepening responses and increased survival for patients with multiple myeloma. In daily clinical pr
Externí odkaz:
https://doaj.org/article/44eb0f2215ae44ac93dbe91263e0cfd0
Autor:
Borja Puertas, Verónica González-Calle, Anna Sureda, María José Moreno, Albert Oriol, Esther González, Laura Rosiñol, Jordi López, Fernando Escalante, Joaquín Martínez-Lopez, Estrella Carrillo, Esther Clavero, Rafael Ríos-Tamayo, Beatriz Rey-Bua, Ana Pilar González-Rodríguez, Victoria Dourdil, Felipe De Arriba, Sonia González, Jaime Pérez-de-Oteyza, Miguel T. Hernández, Aránzazu García-Mateo, Joan Bargay, Joan Bladé, Juan José Lahuerta, Jesús F. San Miguel, Enrique M. Ocio, María-Victoria Mateos
Publikováno v:
Haematologica.
In this randomized phase 2 study (GEM-KyCyDex), the combination of weekly carfilzomib 70 mg/m2, cyclophosphamide and dexamethasone was compared to carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM) after 1-3 prior lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b505357edaccffb072523def1473f22d
https://doi.org/10.3324/haematol.2022.282490
https://doi.org/10.3324/haematol.2022.282490
Autor:
Mª Carmen Herrero-Sánchez, Concepción Rodríguez-Serrano, Julia Almeida, Laura San Segundo, Susana Inogés, Ángel Santos-Briz, Jesús García-Briñón, Luis Antonio Corchete, Jesús F. San Miguel, Consuelo del Cañizo, Belén Blanco
Publikováno v:
Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-14 (2016)
Abstract Background Graft-versus-host disease (GvHD) remains the major obstacle to successful allogeneic hematopoietic stem cell transplantation, despite of the immunosuppressive regimens administered to control T cell alloreactivity. PI3K/AKT/mTOR p
Externí odkaz:
https://doaj.org/article/5fb5dbe4f7ca47b3843e653ce28866c4
Autor:
Elizabeta A. Rojas, Luis A. Corchete, Cristina De Ramón, Patryk Krzeminski, Dalia Quwaider, Ramón García‐Sanz, Joaquín Martínez‐López, Albert Oriol, Laura Rosiñol, Joan Bladé, Juan José Lahuerta, Jesús F. San Miguel, Marcos González, María Victoria Mateos, Jean‐Christophe Bourdon, Irena Misiewicz‐Krzeminska, Norma C. Gutiérrez
Publikováno v:
American Journal of Hematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Loss and/or mutation of the TP53 gene are associated with short survival in multiple myeloma, but the p53 landscape goes far beyond. At least 12 p53 protein isoforms have been identified as a result of a combination of alternative splicing, alternati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::448d1c6742796e670dabd12ef077016d
https://doi.org/10.1002/ajh.26507
https://doi.org/10.1002/ajh.26507